Diploma PLC (PK) (DPMAY) Quote

PDIV A TOXIC SHARE SELLING SCAM

I think the people who live in Svizzera-Italia are supposed to learn German in school. And probably they do learn at least some French. But go to Lugano, and you won't really hear anything but Italian spoken.

We are waiting on an approval decision from the UK.

The expected time frame for that decision is subject of considerable debate.
The range of expectations is from tomorrow to mid 2026.

And let's not forget the likely first catalyst - and possibly the most lucrative - Taiwan!

Simple monkey . . .

Absolutely! We were just there very recently.

KRTL liking what I.m seeing, hearing, next update can be huge
Xstocklpicker88
@xstocklpicker88
$KRTL at .046 is a #25xgem within 60 days imo. The company is an FDA registered pharma company bringing drugs from South America to the U.S. One sales news away from .046-1.00. The sta

And the other 30% speak Danish. My daughter plays on a tennis team in Switzerland. The girls from the Italian part of the country came up to play a match and they didn't even speak German, only Italian. It was the strangest thing.

Did you notice any warnings here on the IHUB Board about this company, its promoters and insiders?

KRTL liking what I.m seeing, hearing, next update can be huge
Xstocklpicker88
@xstocklpicker88
$KRTL at .046 is a #25xgem within 60 days imo. The company is an FDA registered pharma company bringing drugs from South America to the U.S. One sales news away from .046-1.00. The sta

KRTL liking what I.m seeing, hearing, next update can be huge
Xstocklpicker88
@xstocklpicker88
$KRTL at .046 is a #25xgem within 60 days imo. The company is an FDA registered pharma company bringing drugs from South America to the U.S. One sales news away from .046-1.00. The sta

This company just has too much dirty laundry, too much drama, too many x accounts, and too many issued shares to go anywhere. New PR person has only made it worse.

Only thing that's going to fix this is a massive public buyback of shares to push SP up. Money solves many issues

FYI: info regarding Apple is suspected of being false...source of info has apparently been discredited...see links from Hedera reddit posted below...

https://www.reddit.com/r/Hedera/comments/1hlxe2r/shameless/

https://www.reddit.com/r/Hedera/comments/1hm1mqz/people_nee

Can anyone update this board on the status of this company? I appreciate any info. Been here along time but have no idea if we are close to being a success or if we are stuck in the mud. Lol.

Here is the updated sample letter. Anyone here on ihub that wants to add, delete, revise is welcomed.
If Skull decides to take the lead as the signer, let’s see the other shareholders who wants to add their names to the letter once it is finalized. Let’s have a show of hands of the shareho

https://tinyurl.com/fn44uvt3

Did you read the linked article?
Didn't look promising to me.

Well... They can't really expect other people to speak Greenlandic. Which apparently is the language of 70 percent of the people who live there.

On 12/26/17 this board was created by myself and Mr40. That was Seven years ago! It seems like yesterday.

We all hope Mr40 and her little dog Remy are in good spirits and in good hands.

Thank you to all of you who read and contribute to our America Stands With Trump

What are we looking at here buddy? Thanks in advance for any information.

He's really good! It's amazing how perfectly they all speak English.

Interesting. Something is going on. It’s about time. 10 years……let’s go baby!! Maybe it’s time……good luck to all the longs that have stuck it out. Praying for good outcomes not only for us shareholders but patients as well. It can be both. Lol.

Easy on the fetenyl rbtree. Crazy talk is the first sign we are dealing with an addict living in mommy's basement.

AD is a huge indication. The FDA has a duty to understand 2-73 thoroughly before approving it. Investors have a completely different set of priorities and preconceptions. 2-73 (like aducamab and lecanemab) will take 12 months to review and decide.